[2 new antineoplastic derivatives: 9-hydroxy-2-methyl-ellipticinium (acetate) and 9-hydroxy-2,6-dimethyl-ellipticinium (chloride). Effect on mouse L 1210 leukemia].

Abstract

The antitumoral activity of two new derivatives of ellipticine, 9-hydroxy-2-methyl ellipticinium and 9-hydroxy-2,6-dimethyl-ellipticinium, has been determined using L 1210 mouse leukemia. The first compound elicits a therapeutic index similar to that of 9-hydroxy-ellipticine but is active at doses ten times smaller. The second compound elicits an exceptionally high therapeutic index. It is still active when used at one hundredth of the sublethal dose.

• Authors: J B Le Pecq, C Gosse, Nguyen-Dat-Xuong, C Paoletti
• Journal: Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles (C R Acad Hebd Seances Acad Sci D) Vol. 281 Issue 18 Pg. 1365-7 (Nov 03 1975) France
• Vernacular Title: Deux nouveaux dérivés anti-tumoraux: l'hydroxy-9 méthyl-2 ellipticinium (acétate) et l'hydroxy-9 diméthyl-2,6 ellipticinium (chlorure). Action sur la leucémie L 1210 de la souris
• PMID: 815025 (Publication Type: English Abstract, Journal Article)

Chemical References

• Alkaloids
• Ellipticines

Topics

• Alkaloids (therapeutic use)
• Animals
• Ellipticines (administration & dosage, therapeutic use)
• Leukemia L1210 (drug therapy)
• Mice
• Mice, Inbred DBA